- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more
- Conditions
- Blepharospasm
- Interventions
- Botulinum toxin type A
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
- Conditions
- HCV Infection
- Interventions
- placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 48
- States / cities
- Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Chronic Hepatitis B
- Interventions
- NVR 3-778, Placebo for NVR 3-778, Pegasys
- Drug
- Lead sponsor
- Novira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Costa Mesa, California • Pasadena, California • San Diego, California + 1 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Acthar, Placebo, Steroid Drug
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 22
- States / cities
- Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
- Conditions
- Low Testosterone
- Interventions
- TAK-448, TAK-448 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Interventions
- Pramlintide, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia
- Interventions
- TV-44749, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 38 more
- Conditions
- Femur Neck Fracture
- Interventions
- Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
- Drug · Dietary Supplement
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- DCR-AUD, Placebo for DCR-AUD
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Obesity
- Interventions
- bremelanotide, tirzepatide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- COYA 302, Placebo
- Drug
- Lead sponsor
- Coya Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-004, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Critical Limb Ischemia
- Interventions
- Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
- Drug · Other
- Lead sponsor
- Leonardo Clavijo
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
- Conditions
- Diabetes Mellitus, Insulin-Dependent
- Interventions
- INGAP-Peptide, placebo
- Drug
- Lead sponsor
- Exsulin Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 10
- States / cities
- Irvine, California • San Diego, California • Walnut Creek, California + 6 more
- Conditions
- Systemic Lupus Erythematosus Arthritis
- Interventions
- abatacept also known as Orencia also known as CTLA4-Ig, Placebo
- Biological · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Diego, California
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 27
- States / cities
- Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more
- Conditions
- Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- eneboparatide, Placebo
- Combination Product
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
- Conditions
- Addiction, Alcohol Use Disorder
- Interventions
- Take Control, Semaglutide
- Behavioral · Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
- Interventions
- Rilonacept, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland